The results of the TRIO 018 Clinical Trial indicated that the combination of Investigational Agent and Letrozole demonstrated clinical benefit in Advanced ER-positive Breast Cancer.
18 patients in Ireland participated in this study and Prof John Crown was the ICORG Chief Investigator.
Please click here for full press release from the SABCS Meeting.